Alnylam Pharmaceuticals (ALNY) Return on Capital Employed Growth (1y) (2011 - 2026)
Alnylam Pharmaceuticals (ALNY) Return on Capital Employed Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 45.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -785.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,629.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3,193.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 399.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -310.00 |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | -787.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,193.00 |
| Mar 31, 2026 | 2,400.00 |
| Dec 31, 2025 | 2,040.00 |
| Sep 30, 2025 | 1,491.00 |
| Jun 30, 2025 | -942.00 |
| Mar 31, 2025 | 243.00 |
| Dec 31, 2024 | 402.00 |
| Sep 30, 2024 | 675.00 |
| Jun 30, 2024 | 3,526.00 |
| Mar 31, 2024 | 2,210.00 |
| Dec 31, 2023 | 1,847.00 |
| Sep 30, 2023 | 1,647.00 |
| Jun 30, 2023 | -544.00 |
| Mar 31, 2023 | -537.00 |
| Dec 31, 2022 | -355.00 |
| Sep 30, 2022 | -514.00 |
| Jun 30, 2022 | 36.00 |
| Mar 31, 2022 | 555.00 |
| Dec 31, 2021 | 513.00 |
| Sep 30, 2021 | 800.00 |